Results 221 to 230 of about 436,330 (367)

Treatment Patterns and Healthcare Utilization on Pediatric Atopic Dermatitis With Allergic Comorbidities: A Japanese Claims‐Based Study

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic, itchy skin disease that often begins in infancy and may persist into adulthood. The high co‐occurrence of allergic comorbidities (ACMs; asthma, food allergy, and allergic rhinitis) makes it a growing public health concern.
Masaki Futamura, Yumi Kang, Ambrish Singh, Junichi Danjo, Takashi Matsuo, Hitoe Torisu‐Itakura, Mizuho Nagao   +6 more
wiley   +1 more source

Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. [PDF]

Clin Appl Thromb Hemost
Chen Z, Wang S, Wang Y.
europepmc   +1 more source

Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116 [PDF]

Aleksandra Rzewińska, Jakub Szlęk, Damian Dąbrowski, Ewelina Juszczyk, Katarzyna Mróz, Heikki Räikkönen, Mia Sivén, Maciej Wieczorek, Przemysław Dorożyński   +8 more
openalex   +1 more source

THU0193 Reestablishment of efficacy of tofacitinib, an oral janus kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation [PDF]

, 2017
Jeffrey Kaine, John Tesser, Ryan DeMasi, Liza Takiya, L Wang, M.R. Snyder, Hongyan Fan, J. Wollenhaupt   +7 more
openalex   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

Janus kinase inhibitors: another potential for uveitis treatment? [PDF]

Ann Eye Sci
Emami S, Kaisari E, Janetos TM.
europepmc   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis [PDF]

, 2017
Steve Chaplin
openalex   +1 more source

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO‐2b/3 and ALLEGRO‐LT Clinical Studies for Alopecia Areata

The Journal of Dermatology, EarlyView.
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Rie Ueki, Masato Mizuashi, Kazutoshi Harada, Xingqi Zhang, Wenyu Wu, Wen‐Hung Chung, Ohsang Kwon, Xin Luo, Victoria Basey, Robert Wolk, Nanzhi Shi, Kayo Fujita, Yimeng Shen, Tomohiro Hirose   +13 more
wiley   +1 more source

Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors. [PDF]

J Clin Med
Sahin G, Aydin F, Pancar Yuksel E.
europepmc   +1 more source